Excellent case based panel on esophageal cancer moderated deftly by Sam Klempner Exciting that we are discussing TNT and organ preservation for esophageal cancer! #ASCO25

Inspiring talk by Dr. Karen Mustian on her transformative and innovative work in Exercise Oncology! 'Keep some room in your heart for the unimaginable' indeed. #ASCO25 Awesome introduction by @rochgerionc

Why was there no chemo + immunotherapy arm in the LEAP trial as a control? Kohei shitara #ASCO25

Fantastic work Kohei shitara and team on the Destiny Gastric04 study. New standard of care in 2nd line setting 👍 #ASCO25

Impressive results with PAXG regimen in early stage pancreatic cancer! I worry about toxicity in US population with continous Xeloda 1250mg/m2 BID #ASCO25

Congratulations Hani M Babiker MD and team on successful PANOVA-3 trial 🎉 for LA-PC. Key will be how to integrate into our practice. #ASCO25

Clear and nuanced discussion by Sarbajit Mukherjee on the two very different neoadjuvant biliary tract ca 👍 My takeaway is to give neoadjuvant therapy if there is any hesitation at all by surgeon about RO resection #ASCO25

#ASCO25 OG orals take homes: 1. CM577: adj nivo SCC only 🚫 mixed histology trials! 2. LEAP15: chemo+TKI+ICI=too much 🔎 Attention to the safety run-in 3. DG04: TDXD 1.1m PFS 3.3m OS ⬆️ 💉biopsy after 1L 4. CLD 18.2 CAR-T: 4m PFS 🔬 More work needed on tox vs efficacy

A tribute to Dr. Agatsuma was a meaningful moment during my DESTINY-Gastric04 presentation at #ASCO25 with NEJM publication. I deeply respect him and the entire team behind the development of T-DXd. ASCO OncoAlert Daiichi Sankyo Daiichi Sankyo US AstraZeneca Oncology at AstraZeneca

Overall survival hazard ratio in an adjuvant study of 0.63 is really remarkable. And it’s not a $30K/month drug! 👏🏼👏🏼👏🏼 #ASCO25

Fantastic session by Sepideh Gholami, MD, MAS, FACS, FSSO and colleagues on liver directed therapy for CRLM: from SBRT to liver transplant! 5 year 60% OS with transplant in US 👍 #ASCO2025

Fantastic and practical session on how to best attend to the suffering we witness in Oncology : being person-centered vs patient-centered, know your WHY, know your polyvagal response, incredible lessons learnt....#ASCO2025

The most practice changing trial from #ASCO25 is now live on NEJM .If this was a drug, this would be approved today. Globally relevant and low-cost intervention that is not only delaying relapse but actually improving survival. Perfect case example of a #cancergroundshot trial.

Excellent talks and discussion on pancreatic cancer immunotherapy, vaccines and subtypes co-chaired by Tim Brown, MD MSCE Well planned 👍#ASCO2025

Clear and detailed discussion on pancreatic cancer intrinsic subtypes by Peter Hosein, MD I have a much better understanding of PurIST and classical basal subtype spectrum #ASCO2025

Applaud Bishal Gyawali, MD, PhD, FASCO talk on balancing hope and reality in pancreatic cancer 👍 so easy to get caught up in the hype. Important to not bring false hope to our clinic rooms indeed #ASCO2025

Registration is now open for the Orlando Colorectal Congress 2025! Join us to enhance your skills and techniques in colorectal surgery! Learn More! cvent.me/BPwyEN?RefId=L… Mark Soliman, MD, MBA #colorectal #colorectalcancer #coloncancer #colorectalsurgery #colorectalcancerawareness

🚨 STELLAR-303 makes history! First-ever Ph3 trial to show OS benefit of IO in MSS CRC 🎯 Years of grit & belief led us here 🥹 Endless thanks to Exelixis⁩ for the trust & Dr. Hecht for leading this global win with me! 🎉 ⁦UPMC Hillman Cancer Center⁩ ir.exelixis.com/news-releases/…

For dMMR colon cancer, FOLFOX + atezolizumab per ATOMIC is now incorporated into the NCCN Guidelines. Mayo Clinic Comprehensive Cancer Center Alliance for Clinical Trials in Oncology The ASCO Post Colorectal Cancer Alliance Cure GI Cancers Fight Colorectal Cancer

Need my GI Oncology brain trust: 78 yo with new diagnosis unresectable hilar cholangioca. MSI-H with loss of PMS2 and MLH1 expression. Immunotherapy alone? Chemo-immunotherapy?